



Samrat Pharmachem Limited

Manufacturers & Exporters of Pharmaceutical Chemicals

Regd. Office & Factory

Plot No. A2/3445, GIDC,
Phase 4, Ankleshwar – 393 002,
Gujarat, India
Tel : +91-7045456789 / 7046456789
Web: www.samratpharmachem.com

CIN: L24230GJ1992PLC017820

Corporate Office

701/702, Business Square,
M. A. Road, Andheri (West),
Mumbai – 400 058, India
Tel : (91-22) 26701050 / 1 / 2 / 3
Email: contact@samratpharmachem.in

November 14, 2022

To,
**Department of Corporate Services,
BSE Limited**
P J Towers,
Dalal Street,
Mumbai - 400 001.

Scrip Code: 530125

Dear Sir,

Sub: Approval of Unaudited Standalone Financial Results for the quarter and half year ended September 30, 2022

We wish to inform you that the Board of Directors of the Company at its meeting held today i.e. Monday, November 14, 2022, the Board has considered and took on record the Un-Audited Standalone Financial Results of the Company for the quarter and half year ended September 30, 2022, which is enclosed herewith along with the Statement of Asset & Liabilities, Cash Flow Statement and the Limited Review Report of the Statutory Auditor of the Company.

The meeting of the Board of Directors of the Company commenced at 14:00 hrs and concluded at 15:30 hrs.

Kindly inform all your members.

Thanking you,

Yours faithfully,
For Samrat Pharmachem Limited

Nishant Kankaria
Company Secretary & Compliance Officer



Samrat Pharmachem Limited

Manufacturers & Exporters of Pharmaceutical Chemicals

Statement of Standalone Unaudited Results for the Quarter Ended 30 September, 2022

(Rupees in Lakhs)

Particulars	Quarter Ended 30-Sep-22 (Unaudited)	Quarter Ended 30-Jun-22 (Unaudited)	Quarter Ended 30-Sep-21 (Unaudited)	Year to date ended 30-Sep-22 (Unaudited)	Year to date ended 30-Sep-21 (Unaudited)	Year Ended 31-Mar-22 (Audited)
1 (a). Revenue from Operations	7,111.75	8,650.67	5,907.62	15,762.42	10,631.49	22,181.17
(b). Other Income	15.93	2.54	7.25	18.46	22.56	55.08
Total Revenue	7,127.68	8,653.21	5,914.87	15,780.88	10,654.05	22,236.25
2. Expenditure						
a) Cost of materials consumed	6,874.54	7,567.02	5,213.81	14,441.56	9,709.62	19,023.42
b) Purchase of Traded Goods	0.00	0.00	0.00	0.00	0.00	0.00
c) Change in Inventories of Finished Goods and Work-in-Progress	-821.34	-413.57	116.79	-1,234.91	51.62	-33.33
d) Employee Costs	43.17	41.15	39.84	84.32	77.86	177.47
e) Finance Cost	23.60	22.61	20.66	46.21	38.09	67.45
f) Depreciation & Amortisation expense	15.99	15.77	14.76	31.76	29.25	59.47
g) Other Expenses	189.68	167.55	121.89	357.23	234.68	579.28
(i) Manufacturing Expenses	88.75	96.01	76.48	184.75	165.92	376.66
(ii) Administration Expenses	29.36	32.02	18.55	61.38	32.45	93.35
(iii) Selling & Distribution Expenses	71.57	39.52	26.86	111.10	36.31	109.27
Total	6,325.64	7,400.53	5,527.75	13,726.17	10,141.12	19,873.76
3. Profit before exceptional & extraordinary items & tax	802.04	1,252.68	387.12	2,054.71	512.93	2,362.49
4. Exceptional Items	0.00	0.00	0.00	0.00	0.00	-2.34
5. Profit before extraordinary items & tax	802.04	1,252.68	387.12	2,054.71	512.93	2,360.15
6. Extraordinary items	0.00	0.00	0.00	0.00	0.00	0.00
7. Profit before tax	802.04	1,252.68	387.12	2,054.71	512.93	2,360.15
8. Tax expense						
a) Current Tax	-221.65	-312.95	-94.42	-534.60	-124.25	-638.82
b) Deferred Tax	10.89	-3.08	-13.75	7.81	-14.35	-2.84
Total Tax Expense	-210.76	-316.03	-108.17	-526.79	-138.60	-641.66
9. Profit (Loss) for the period after tax	591.28	936.65	278.95	1,527.92	374.33	1,718.49
10. Other Comprehensive Income (OCI)						
a(i) Items that will not be re-classified to profit and loss	0.00	0.00	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will not be re-classified to profit and loss	0.00	0.00	0.00	0.00	0.00	0.00
b(i) Items that will be re-classified to profit and loss	0.00	0.00	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will be re-classified to profit and loss	0.00	0.00	0.00	0.00	0.00	0.00
Total Other comprehensive income, net of income tax	0.00	0.00	0.00	0.00	0.00	0.00
11. Total Comprehensive Income for the period	591.28	936.65	278.95	1,527.92	374.33	1,718.49
12. Paid-up Equity Share Capital (Face Value Rs.10)	308.97	308.97	308.97	308.97	308.97	308.97
13. Earnings per equity share						
a) Basic	19.14	30.32	9.03	49.45	12.12	55.62
b) Diluted	19.14	30.32	9.03	49.45	12.12	55.62



Samrat Pharmachem Limited

Manufacturers & Exporters of Pharmaceutical Chemicals

Notes:

1. The above results were reviewed by the Audit Committee of the Board of Directors.
2. The Statutory Auditors have carried out a limited review of the results for the quarter ended 30 September, 2022.
3. The above unaudited results have been taken on record by the Board of Directors at its Meeting held on Monday, 14 November 2022 at the Corporate Office of the Company.
4. The Company has adopted Indian Accounting Standards ('Ind AS') notified by the Ministry of Corporate Affairs with effect from 01 April 2017 (with a transition date of 01 April 2016). Accordingly the financial results for the quarter ended 30 September 2022 have been prepared in accordance with Companies (Indian Accounting Standard) Rules, 2015 as prescribed under section 133 of the Companies Act, 2013.
5. The Company manufactures pharmaceutical chemicals, which is a single business segment.
6. Figures for the previous period have been regrouped / reclassified, wherever necessary.

**By order of the Board of Directors
For Samrat Pharmachem Limited**

**Rajesh Mehta
Executive Director
DIN: 00216731**



Place : Mumbai

Date : 14 November 2022



Samrat Pharmachem Limited

Manufacturers & Exporters of Pharmaceutical Chemicals

Statement of Assets & Liabilities

PARTICULARS	(Rs. in lakhs) (Rs. in lakhs)	
	Standalone	Standalone
	AS ON 30-Sep-22 Un-Audited	AS ON 31-Mar-22 Audited
ASSETS		
Non Current Assets		
Property, Plant and Equipment	982.82	997.72
Capital Work-in-progress	-	0
Intangible Assets	0.80	0.84
Intangible Assets under development	-	0
Financial Assets		
Investments	-	-
Loans	23.40	20.57
Deferred Tax Assets (Net)	-	-
Other Non-Current Assets	181.13	59.70
Total Non Current Assets	1,188.15	1,078.83
CURRENT ASSETS		
Inventories	3,381.87	1,241.60
Financial Assets		
Investments	189.16	1.00
Trade Receivables	5,370.02	4,357.46
Cash And Cash Equivalents	898.10	1,726.75
Loans	-	1.50
Other Financial Assets	-	-
Other Current Assets	72.54	54.05
Total Current Assets	9,911.69	7,382.36
Total- Assets	11,099.84	8,461.19
EQUITY AND LIABILITIES		
Equity		
Equity Share Capital	308.97	308.97
Other Equity	5,901.13	4,373.20
Total Equity	6,210.10	4,682.17
Non-Current Liabilities		
Financial Liabilities		
Borrowings	683.58	-
Provisions	-	-
Deferred Tax Liabilities (Net)	38.28	46.09
Other Long Current Liabilities	-	-
Total Non-Current Liabilities	721.86	46.09
Current Liabilities		
Financial Liabilities		
Borrowings	2,179.53	751.97
Trade Payables	1,445.78	2,334.10
Other Financial Liabilities	-	-
Other Current Liabilities	7.66	87.72
Provisions	534.91	559.14
Total Current Liabilities	4,167.88	3,732.93
Total Liabilities	11,099.84	8,461.19



Samrat Pharmachem Limited

Manufacturers & Exporters of Pharmaceutical Chemicals

CASH FLOW STATEMENT FOR THE HALF YEAR ENDED 30 SEPTEMBER, 2022

(Rupees in Lakhs)

Particulars	Half year ended 30/Sep/2022 (Unaudited)	Half year ended 30/Sep/2021 (Unaudited)
A. CASH FLOW FROM OPERATING ACTIVITIES		
Profit / (Loss) before tax	2,054.71	512.92
Adjustments For :		
Depreciation and amortization expense	31.76	29.25
(Gain) / Loss on Sale/write off of property, plant and equipment and intangible assets, net	0.00	-0.37
Finance Cost	46.21	38.09
Interest Income	-4.45	-3.45
Dividend Income on investments	-9.86	-0.17
Net gain on sale of investments measured at fair value through profit or loss	-8.94	0.00
Net loss arising on financial assets measured at fair value through profit or loss	0.00	0.00
Net gain on sale of arising on financial assets measured at fair value through profit or loss	0.00	0.00
Net (gain)/ loss on sale of financial assets measured at fair value through profit or loss	0.00	0.00
Gain On Sale of Investment in subsidiary	0.00	0.00
Provision/write off/ (reversal) for doubtful trade receivables /	0.00	0.00
Sundry balances written back, net	0.00	0.00
Provision in respect of losses of a subsidiary	0.00	0.00
Effect of exchange rate changes	0.00	0.00
	54.72	63.35
Operating Profit Before Working Capital Changes	2,109.43	576.27
Movements in working capital:		
(Increase) / decrease in inventories	-2,140.28	-27.92
(Increase) / decrease in trade receivables	-1,012.56	-1,215.90
(Increase) / decrease in other assets	-21.62	-71.91
Increase / (decrease) in trade payables	-894.64	1,171.59
Increase / (decrease) in other liabilities	-80.05	44.67
Increase / (decrease) in provisions	0.00	0.15
	-4,149.15	-99.32
Cash Generated From Operations	-2,039.72	476.95
Income Tax Paid (net of refund)	-672.14	-102.59
Net cash generated from operating activities (A)	-2,711.86	374.36
B. CASH FLOW FROM INVESTING ACTIVITIES		
Payments for purchase of property, plant and equipment (including capital work-in-progress, intangible assets and intangible)	-16.81	-34.58
Proceeds from disposal of property, plant and equipment and intangible assets	0.00	0.00
Loans / Inter corporate deposits given / placed	0.00	0.00
Loans / Inter corporate deposits received back / matured	0.00	0.00
Purchase of investments	-179.22	0.00
Proceeds from sale / redemption of investments	0.00	0.00
Bank balances not considered as cash and cash equivalents		
Fixed deposits / margin money placed	-225.00	-80.00
Fixed deposits / margin money matured	0.00	0.00
Interest received	4.45	3.45
Dividend received	9.86	0.17
Net cash from investing activities (B)	-406.72	-110.96
Continued ...		



Samrat Pharmachem Limited

Manufacturers & Exporters of Pharmaceutical Chemicals

Particulars	30/09/2022 Rs.	30/09/2021 Rs.
C. CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds From Issue of equity shares on exercise of stock options /	0.00	0.00
Proceeds from borrowings	2,111.14	185.08
Repayment of borrowings	0.00	-87.25
Finance costs	-46.21	-38.09
Dividend paid	0.00	0.00
Dividend distribution tax	0.00	0.00
Net Cash from / (Used) In Financing Activities (C)	2,064.93	59.74
NET INCREASE/ (DECREASE) IN CASH AND CASH EQUIVALENTS (A+B+C)	-1,053.65	323.14
CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE PERIOD (Opening Balance)	1,470.35	27.86
EFFECT OF EXCHANGE DIFFERENCES ON RESTATEMENT OF FOREIGN CURRENCY CASH AND CASH EQUIVALENTS	0.00	0.00
CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD (Closing Balance)	416.70	351.00

By order of the Board of Directors

For Samrat Pharmachem Limited



Rajesh Mehta
Executive Director
DIN: 00216731



Place : Mumbai
Date : 14 November 2022



Shah & Savla LLP

Chartered Accountants

CA Mulesh Savla
Advisory & Regulatory

CA Nilesh Dedhia
Direct Tax & Litigation

CA Miral Nagda
Audit & Assurance


CA Nihar Dharod
Indirect Tax & Litigation

Independent Auditor's Review Report on Quarterly and Year-to-date Unaudited Financial Results of the Company pursuant to the regulation 33 of SEBI (Listing obligations and Disclosure Requirements) Regulation, 2015, as amended

To the Board of Directors of Samrat Pharmachem Limited

1. We have reviewed the accompanying statement of unaudited financials result of Samrat Pharmachem Limited, for the Quarter ended 30th September, 2022 and year to date results for the period from 01 April 2022 to 30 September 2022 (the "statement") attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, as amended.
2. This statement, which is the responsibility of the Company's Management and approved by the Board of Directors / Committee of Board of Directors has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34), prescribed under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the statement based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim financial information performed by Independent Auditor of the entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatements. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with standards on auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards (Ind AS) specified under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Shah & Savla LLP
Chartered Accountants
Firm Reg: No.:109364W/W100143


CA. Mulesh M. Savla
(Partner)
Membership No. 038404



UDIN : 22038404BDBAQE5426

Place: Mumbai

Date: 14th November, 2022

Office : 201-RNJ Corporate, Jawahar Road, Ghatkopar (East), Mumbai - 400077, INDIA.
T : (022) 6153 5500 / 2501 0700 | E : info@shahnsavla.com | W : www.shahnsavla.com